Heron Therapeutics, Inc. — 2014 Q2 Form 10-Q Summary
Business Context and Reporting Period
Heron Therapeutics, formerly A.P. Pharma, is a specialty pharmaceutical company developing injectable drug-delivery products using its Biochronomer polymer platform. The filing covers the three and six months ended June 30, 2014, with unaudited financial statements.
- Lead candidate: SUSTOL, for prevention of acute and delayed chemotherapy-induced nausea and vomiting.
- A 1,000-patient Phase 3 SUSTOL study for delayed CINV in highly emetogenic chemotherapy was initiated in 2014 and was expected to be completed in late 2014.
- HTX-011, a sustained-release post-surgical pain candidate, was expected to enter human clinical studies in the second half of 2014.
- The company changed its name to Heron Therapeutics and completed a one-for-20 reverse stock split effective January 13, 2014.
Financial Metrics
| Metric | Three Months Ended June 30, 2014 | Three Months Ended June 30, 2013 | Six Months Ended June 30, 2014 | Six Months Ended June 30, 2013 |
|---|---|---|---|---|
| Revenue | No revenue reported | No revenue reported | No revenue reported | No revenue reported |
| Research and development expense | $14.4 million | $10.8 million | $26.2 million | $17.9 million |
| General and administrative expense | $4.4 million | $4.4 million | $9.9 million | $10.0 million |
| Total operating expenses | $18.8 million | $15.2 million | $36.1 million | $28.0 million |
| Net loss | $19.0 million | $15.4 million | $36.5 million | $28.4 million |
| Net loss per share | $0.78 | $1.01 | $1.52 | $1.86 |
| Cash flow from operations | Not separately reported for the quarter | $(28.2) million | $(18.8) million |
- Cash increased to $105.0 million at June 30, 2014 from $72.3 million at December 31, 2013.
- Financing activities provided $61.2 million during the first six months, including $58.9 million of net proceeds from a June common-stock and pre-funded warrant offering and $2.3 million from stock-option exercises.
- Accumulated deficit was $275.4 million at June 30, 2014.
- Current liabilities were $10.8 million, including $1.3 million of convertible notes payable, net of discount.
- The convertible notes had $5.2 million of principal outstanding, bear 6% interest, and may be prepaid at the holders’ option. Conversion would result in approximately 6.5 million shares.
- Operating lease obligations totaled $2.0 million, including $0.9 million due within one year.
Material Changes Versus the Prior Comparable Period
- Six-month research and development expense increased 46% to $26.2 million, primarily because of the SUSTOL Phase 3 label-expansion study, other SUSTOL activities, HTX-011 development, and increased personnel costs.
- Three-month research and development expense increased 34% to $14.4 million.
- Six-month net loss increased 29% to $36.5 million, reflecting higher research and development spending and continued absence of product revenue.
- Six-month operating cash use increased to $28.2 million from $18.8 million.
- Cash improved despite operating losses because of the June 2014 equity financing and stock-option exercises.
- General and administrative expense was broadly stable year over year.
- Weighted-average shares increased to 24.0 million for the first six months from 15.3 million, primarily reflecting equity financing and other share issuances. Basic and diluted loss per share declined because of the larger share base.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected to resubmit the SUSTOL NDA during the fourth quarter of 2014. The prior FDA Complete Response Letter identified unresolved manufacturing, administration, and efficacy-analysis issues.
- Management stated that existing working capital was sufficient to fund essential operations into 2015. Additional capital would be required for additional clinical studies, SUSTOL commercialization preparations, or broader pipeline development.
- The company has no material operating cash flows and expects continued substantial losses until it can generate meaningful product revenue.
- Key risks include failure or delay of SUSTOL approval, additional FDA requests, clinical-trial failure, manufacturing deficiencies or supply interruptions, inability to build a commercial organization, competition, intellectual-property challenges, and inability to obtain financing on acceptable terms.
- SUSTOL is manufactured by third parties, and deficiencies at third-party manufacturing facilities contributed to prior FDA concerns.
- The company reported no material changes to previously disclosed legal proceedings and no off-balance-sheet arrangements.
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level, with no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Progress and results of the Phase 3 SUSTOL study and the timing and contents of the planned fourth-quarter 2014 NDA resubmission.
- Whether the company can resolve FDA manufacturing, administration, and efficacy issues and obtain approval without additional clinical or manufacturing work.
- Cash runway relative to the planned SUSTOL commercialization effort and HTX-011 development program.
- Potential dilution from approximately 7.0 million outstanding stock options, 4.4 million warrants, 6.5 million shares underlying convertible notes, and 600,000 pre-funded warrants.
- Terms and holder rights associated with the secured convertible notes, including the holders’ ability to require prepayment.
- Dependence on third-party manufacturers and single-source suppliers, including the ability to scale SUSTOL production at acceptable cost and quality.